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ABSTRACT
Inhibition of Mycobacterium tuberculosis (Mtb) cell wall
assembly is an established strategy for anti-TB
chemotherapy. Arabinosyltransferase EmbB, which
catalyzes the transfer of arabinose from the donor dec-
aprenyl-phosphate-arabinose (DPA) to its arabinosyl
acceptor is an essential enzyme for Mtb cell wall syn-
thesis. Analysis of drug resistance mutations suggests
that EmbB is the main target of the front-line anti-TB
drug, ethambutol. Herein, we report the cryo-EM struc-
tures of Mycobacterium smegmatis EmbB in its “resting
state” and DPA-bound “active state”. EmbB is a fifteen-
transmembrane-spanning protein, assembled as a
dimer. Each protomer has an associated acyl-carrier-
protein (AcpM) on their cytoplasmic surface. Confor-
mational changes upon DPA binding indicate an asym-
metric movement within the EmbB dimer during
catalysis. Functional studies have identified critical
residues in substrate recognition and catalysis, and
demonstrated that ethambutol inhibits transferase
activity of EmbB by competing with DPA. The structures
represent the first step directed towards a rational
approach for anti-TB drug discovery.
KEYWORDS Mycobacterium tuberculosis, EmbB, cryo-
EM, ethambutol, cell wall synthesis, arabinoglacatan,
arabinosyltransferase, acyl-carrier-protein, drug discovery
INTRODUCTION
Tuberculosis (TB) caused by Mycobacterium tuberculosis
(Mtb) is, worldwide, the leading cause of human fatalities
due to any infectious disease (WHO, 2018). Of great con-
cern is the emergence of multi-drug-resistant (MDR)-TB and
extensively drug-resistant (XDR)-TB, which has further
exacerbated the global burden of TB and at the same time
continues to lead to a reduction in clinical recovery rates
(WHO, 2018).
Ethambutol (EMB) is one of the five front-line drugs used
to treat TB and is particularly important in MDR-chemother-
apy regime (Alliance, 2008). It exhibits its mode of action by
inhibiting the biosynthesis of arabinogalactan (AG)
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(Takayama and Kilburn, 1989; Mikusova et al., 1995; Lee
et al., 2005), a key component of the Mtb cell wall mycolyl-
arabinogalactan-peptidoglycan (mAGP) complex (Jankute
et al., 2015). However, the molecular basis for this inhibition
has remained unresolved (Mikusova et al., 1995). Resis-
tance to ethambutol has been shown to be caused by
mutations within the embCAB operon (embC, embA, and
embB) that encode membrane-associated arabinosyltrans-
ferases, amongst which EmbB has been identified as the
primary target (Safi et al., 2008; Sun et al., 2018). Functional
studies have shown that all the Emb proteins play key roles
in cell wall synthesis. Specifically, EmbA and EmbB partici-
pate in arabinosylation of AG, which is linked via covalent
attachment to the outer mycolic acids layer and the inner
peptidoglycan layer, ultimately forming the cell wall core
(Escuyer et al., 2001), thus acting as a natural barrier sur-
rounding the cell membrane (Fig. 1A). On the other hand,
EmbC is involved in the formation of lipoarabinomannan
(LAM), a glycolipid which may modulate the host immune
response during Mtb infection (Goude et al., 2008).
The embB gene has been shown to be essential for the
survival of Mtb in culture (Sassetti et al., 2003), whereas a
Mycobacterium smegmatis (Msm) embB-knockout strain
was shown to be viable but possessed profound morpho-
logical alterations upon gene inactivation (Escuyer et al.,
2001). Furthermore, EmbB has been shown to play a key
role in forming the characteristic terminal hexarabinofura-
nosyl motif (Fig. 1A) of AG, which is the template for
mycolylation (Escuyer et al., 2001; Jankute et al., 2015).
Together with the other Emb proteins (EmbA and EmbC),
EmbB belongs to the glycosyltransferase C (GT-C) super-
family (Berg et al., 2007; Lairson et al., 2008), whose
structures comprises an N-terminal transmembrane domain
and a C-terminal soluble domain located on the periplasmic
side of the membrane (Berg et al., 2007). However, the Emb
proteins show no overall sequence similarity to any other
GT-C members or any other proteins beyond mycobacteria
or related genera (Berg et al., 2005). The lipid donor utilized
by EmbB is decaprenyl-phosphate-arabinose (DPA), which
is the only proven arabinose donor for mycobacterial species
(Lee et al., 1997). In a very recent study three dimensional
structures of Mtb and Msm EmbA-EmbB heterodimer com-
plexes and Msm EmbC2 homodimer complex were deter-
mined (Zhang et al., 2020). Nevertheless, embA knockout
Msm (斜体) strain can survive, indicating EmbB protein can
work alone in cell (Escuyer et al., 2001). However, other
fashions of the Emb-containing assembly, i.e. (斜体), EmbB
as an individual protein has not been reported.
Here, we have characterized EmbB in terms of its struc-
ture, catalytic mechanism and its inhibition by ethambutol.
We present the cryo-EM structures of a full-length Msm
EmbB in two distinct conformations, which we refer to as the
“resting” and donor-bound “active” states at 3.6 Å and 3.5 Å
resolution, respectively. EmbB is observed as a dimer along
with an acyl-carrier-protein (AcpM) associated with each
protomer, thus forming a heterotetrameric EmbB2-AcpM2
complex. We show that ethambutol inhibits the enzymatic
activity of the EmbB2-AcpM2 complex and structurally iden-
tify the site that is most susceptible to ethambutol resistance
based on isolates from clinical studies.
Galf
L-Rhamnose
GlcNAc-1-Phosphate
Phosphate
Peptidoglycan
Arabinofuranosyl (Araf)
Hexa-arabinofuranosyl (Araf6)
Acceptor
EmbB
Product
(Araf6 motif) HO OH
OH
OH
  Following reaction 
catalyzed by AftB
Cell Wall
Cell Membrane
MycobacteriumPeptidoglycan (PG)
OH
O(CH2)7CH3
NV6
EmbB
DPA
DP
O
O ODPDPA
(Donor)(By-product
C50P)
A B
HO
HO
OH
OH
OH
OH
NV12
OH
O
O OO
O
O(CH2)7CH3
Ethambutol
EmbB
NV6
DP[14C]A
Origin
NV12 (RF = 0.39)
Solvent front
+--
++-
+++
+++
Mycolic acid (MA)
Arabinogalactan
(AG)
Figure 1. Arabinosyltransferase activity of EmbB and inhibition by ethambutol. (A) Schematic representation of the
components and assembly of the mycobacterial membrane and cell wall. EmbB catalyzes the addition of an arabinose residue in an
α(1→3) linkage from DPA resulting in the precursor for a subsequent extension by AftB, further resulting in the characteristic terminal
branching hexamotif found in AG. (B) Arabinosyltransferase activity measured using di-arabinoside NV6. The [14C] labeled arabinose
transferred from DP[14C]A to the product was confirmed by autoradiographic thin layer chromatography (TLC). See also Figures S1
and S9.
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RESULTS AND DISCUSSION
Enzyme purification, characterization and structure
determination
To gain insights into the structure and function of EmbB, we
screened several mycobacterial orthologues to assess pro-
tein yield and purity. From these studies, we identified Msm
EmbB (MSMEG_6389) as the ideal candidate for investi-
gation. Msm EmbB, whose sequence is 69.6% identical to
Mtb EmbB (Rv_3795) was cloned into the pMV261 vector
containing a 10× His tag fusion at its C-terminus. Msm was
then used as its host for overexpression (Snapper et al.,
1990). Detergent purified followed by amphipol exchanged
EmbB protein (Fig. S1A–C) was then subjected to cryo-EM
analysis.
The natural acceptor of EmbB remains to be defined, but
cell-free arabinosyltransferase activity could be measured
using a diarabinoside, NV6, as an acceptor analog (Fig. 1B).
An EmbB arabinosyltransferase assay was used to deter-
mine the transfer of [14C]-arabinose from DP[14C]A to NV6.
The resulting product, NV12, was identified by autoradio-
graphic thin-layer chromatography (TLC) (Fig. 1B). NV12
had a similar retardation factor to a synthetic tri-arabinoside
suggesting the transfer of a single [14C]-arabinose unit from
DP[14C]A, a feature common to these acceptor analogs (Lee
et al., 1997). Not surprisingly, EmbB arabinosyltransferase
activity is inhibited by ethambutol (Fig. 1B). Given NV6
allows three potential glycosylation sites at 2-OH, 3-OH and
5-OH on the terminal non-reducing arabinose, we sought to
use a chemical biology approach to further characterize the
[14C]-arabinose containing NV12 product. The related NV13
acceptor, where the 3-OH position of the terminal arabinose
unit of NV6 is blocked by an azide group was used in sub-
sequent cell-free experiments for purified EmbB, EmbC, and
the abundant AftB activity from Msm membranes (Lee et al.,
1997), to determine the resulting new glycosidic linkage in
NV12 catalyzed by EmbB, which is presumably an α(1→3)-
linkage based on previous studies (Escuyer et al., 2001).
The azide group in NV13 prevented glycosylation by EmbB
but allowed purified EmbC to catalyze an ethambutol-sen-
sitive α(1→5)-linkage (NV15), and an ethambutol-resistant
AftB β(1→2)-linkage (NV14) (Fig. S1E). In addition, 2D
heteronuclear single quantum correlation (HSQC) NMR
experiments using purified AG from wild type Msm and the
Msm embB knockout strain were consistent with the above
cell-free arabinosyltransferase data and showed that the cell
wall from the knockout strain lacked the terminal linkage of
arabinose unit by virtue of the absence of the characteristic
2-α-Araf-3 NMR signal (Fig. S1F).
Purified, amphipol exchanged EmbB appeared as
homogeneous and dispersed particles in negative staining
EM and when embedded in vitreous ice (Fig. S2A). 2D class
averages revealed a dimeric assembly of EmbB (Fig. S2B)
with two attachments on the cytoplasmic side, subsequently
identified by silver staining (Fig. S1C) and mass-
spectrometry (Fig. S1D) as the endogenous acyl-carrier-
protein AcpM (MSMEG_4326). Two major classes gener-
ated by 3D classification were selected and subjected to
individual refinements, ultimately yielding two different
reconstructions at 3.5 Å and 3.6 Å overall resolution
(Fig. S2C-F). The quality of both maps allowed us to build,
de novo, two near-atomic models of EmbB that include most
of the residues (Tables S1 and S2), while AcpM could be
docked and refined using a homologous structure (PDB:
1KLP (Wong et al., 2002)). Additional features in the cryo-
EM map could be accounted for by the donor substrate,
DPA, whose presence was confirmed by mass spectrometry
(Fig. S1G). This feature shows DPA is bound in its expected
binding cavity in the asymmetric EmbB dimer, and the
potential by-product, decaprenyl phosphate (DP) bound to
regions that are likely in the transmembrane domain of
EmbB.
Two distinct states of EmbB2-AcpM2 complex
The EmbB2-AcpM2 complex is captured in two states, one
with C2-symmetry and the other that is asymmetric (Fig. 2A).
In both reconstructions, each EmbB protomer is associated
with an AcpM on its cytoplasmic side (Fig. 2A), resulting in a
heterotetrameric assembly. Given their differences in com-
position and conformation, the two states are referred to as
the asymmetric “donor-bound” active state and the sym-
metric “resting” state (Fig. 2A). The asymmetry refers not
only to the asymmetric binding of DPA, but also to the
asymmetry of the enzyme dimer assembly (see below). The
EmbB protomers in the two states share common structural
features which include two periplasmic domains (PDs) and
15 transmembrane helices (TMH) arranged into an approx-
imately crescent-shaped bundle (Fig. 2B–E). The PDs
comprise a PDN located between TMH1 and TMH2 and a
PDC at the C-terminus (Fig. 2B and 2C). PDC features a jelly-
roll-fold subdomain coordinated with a Ca2+ ion, similar to
the previously reported crystal structure of the C-terminal
soluble domain of EmbC from Mtb (Alderwick et al., 2011),
and a mixed α/β fold subdomain, whose interactions with
both the TM domain and PDN are observed here in the intact
EmbB structure (Figs. 2C, S3B and S3C). PDN also adopts a
jelly-roll-fold and interacts with the C-terminal tail of PDC by
forming a three-stranded β-sheet (Figs. 2B, 2C and S3C),
which may help to stabilize the entire PD. Not surprisingly,
this overall folding represented by EmbB2-AcpM2 complex
agrees well with that of the previously reported Emb proteins
(Zhang et al., 2020).
The two EmbB2-AcpM2 complexes show significant dif-
ferences in their subunit organizations (Fig. 2A, and 2D–G).
Most significantly, the two EmbB protomers in the DPA
bound complex are asymmetrically associated. Relative to
the DPA-bound protomer, the other EmbB protomer is
translated by ∼16 Å along the dimer interface, and in the
plane of the membrane (Fig. 2D and Movie S1). This change
in subunit organization dramatically alters the dimer
Cryo-EM snapshots of EmbB2-AcpM2 RESEARCH ARTICLE
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interface, in which, for instance, the distance between the
pair of TMH11 at the interface has halved, resulting in a more
compact active site (Fig. 2E). While this asymmetric move-
ment is induced, the expected steric clashes in the
periplasmic domains of the two EmbB protomers are
resolved by rearrangements of the PLs and PDs within the
unbound protomer (Fig. 2F, 2G, and Movie S1).
DPA binding in the active complex
In the “active” complex, a semi-confined gulf is formed in the
membrane space that is surrounded by TMH1, TMH7-9 and
TMH11 from the DPA-bound EmbB protomer and TMH10,
TMH13, and TMH14 from the other protomer (Figs. 2E, 3A
and 3B). Once the nearby side-chains were assigned
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Figure 2. Architecture and asymmetry in the EmbB2-AcpM2 complex. (A) Top row: Cartoon representation of the “resting” state
(left) and “donor-bound” active state (right). DPA is drawn as red spheres. Bottom row: Cryo-EM maps of the two states, DPA is buried
inside and is not shown in the map (bottom right). (B) Structure of an EmbB protomer viewed from the dimer interface, with a spectral
coloring from purple (N terminus) to red (C terminus), the mixed α/β subdomain of PDC has colored red and jellyroll fold subdomain in
light brown. (C) Topology diagram for an EmbB protomer using the same color scheme as (B). (D) Superposition of the “resting” and
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Figs. S2, S3 and S4 and Table S1, S2.
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(Fig. S4), the cryo-EM map shows a long tadpole-shaped
signal in the hydrophobic groove formed by TMH7-9, head-
ing to the presumed active site which is expected to be in the
periplasmic space (Fig. 3B and 3C). Given that endogenous
DPA was identified during purification (Fig. S1G), it was
reasonable to build a DPA into this region (Fig. 3A and 3B).
The whole of the DPA fits into this part of the map with the
arabinose moiety and phosphate group fitting into a charged
cavity just above the membrane surface (Fig. 3C and 3D).
This cavity is bordered by PL2 which contains the catalyti-
cally relevant D(285)D(286)x motif (Berg et al., 2005); PL5
which is organized as two short α-helices (α5 and α6) and a
following loop region; and the mixed α/β subdomain of PDC
(Fig. 3C). As a result of DPA binding, several residues
around DPA are repositioned (Fig. 3D). For instance, the
phosphate group is coordinated in place by R495PL5, while
the arabinose moiety forms hydrogen bonds with E313PL2
and Q431PL4 which themselves are further stabilized by
N304PL2 and Y320PL2 (Fig. 3D). W505α6 and T518 on PL5
also hold the DPA headgroup from the other side of the
cavity (Fig. 3D). Most of the residues in this cavity are highly
conserved amongst mycobacterial EmbB proteins (Fig. S8),
and mutations within this hydrophilic cavity result in severe
loss of the arabinosyltransferase activity (Figs. S5A and 5B).
The last seven prenyl groups of DPA extend to the other half
of the hydrophobic groove via extensive hydrophobic inter-
actions with I421TMH7, V438TMH8, I448TMH8, I468TMH9 and
I469TMH9 in the membrane space, with the end of the tail
interacting with F670TM14 from the other EmbB protomer
(Fig. 3E). Collectively, the PLs, PDC, TMH7, bended TMH8,
TMH9 of the DPA-bound EmbB protomer and the TMH14
from the other protomer shape an ideal environment to
accommodate DPA in the active state of the complex.
Another structural rearrangement upon DPA binding, by
comparing the structures of the two states, involves α6 in
PL5, a short α helix that interacts with DPA, whereas in the
resting state, this region is disordered (Fig. 3F). Considering
that the bound DPA is the major composition difference
between the two states, it is reasonable to speculate that the
dramatic structural rearrangement of the enzyme complex in
the active state occurs upon DPA binding, and is mediated
by the induced disorder-to-helix transition of α6 at the dimer
interface. This kind of concerted disordered-to-helix transi-
tion of a functional periplasmic loop along with donor binding
has been proposed to enable access to the acceptor in other
glycosyltransferases such as ArnT from Cupriavidus metal-
lidurans in complex with its lipid substrate undecaprenyl
phosphate (UndP) and PglB from Campylobacter lari with
lipid-linked oligosaccharide (LLO) (Lizak et al., 2011; Vasi-
leios I. Petrou et al., 2016; Napiorkowska et al., 2017).
EmbB-AcpM interaction
AcpM has a four-helix topology arranged in a right-handed
bundle held together by interhelical hydrophobic interactions
(Wong et al., 2002) (Fig. 2C). The two AcpM molecules bind
to each of the two EmbB protomers through extensive
electrostatic interactions on the cytoplasmic surface of
EmbB (Fig. 4A). Helix-2 and helix-3 of AcpM are intimately
engaged with the cytoplasmic loop 1 (CL1) of EmbB, which
is a long positively charged linker between TMH2 and TMH3
(Fig. 4A). This is consistent with the known role of helix-2 in
AcpM as a contact site with its target proteins, such as AcpS
(Parris et al., 2000) (Fig. S6). The AcpM attached to the
DPA-bound EmbB protomer has the better-resolved struc-
ture in our cryo-EM reconstructions (Figs. S2C, S2F, and
S4B). Most of its side-chains have been assigned
(Table S2). Three pairs of interactions are revealed: D53 and
D61 of AcpM form salt-bridges with R454TMH8b and R249CL1
of EmbB, and S41AcpM forms a hydrogen bond with R253CL1
of EmbB (Fig. 4A). R249CL1, R253CL1, and R454TMH8b in
EmbB are highly conserved across mycobacterial species
(Fig. S8). When a triple-alanine mutant (R249, R253, and
R454) of EmbB that abolished its interaction with AcpM
(Fig. S1C) was transformed into Msm embB knockout strain,
a moderate loss (at ∼40%) of the 3-arm branching signal of
AG was observed (Fig. S1G), suggesting that AcpM is most
likely functionally associated to arabinosyltransferase activ-
ity in vivo, regardless the equivalent mutation had little effect
on the cell-free arabinosyltransferase activity (Fig. S5A).
Active site and possible acceptor pathway
Glycosyltransferases are classified as either “inverting” or
“retaining” based on two stereochemical outcomes in the
Figure 3. DPA binding cavity in EmbB. (A) Left: Cartoon
representation of the EmbB2-AcpM2 complex in the “donor-
bound” active state. Right: Cavity formed in the membrane
space surrounded by TMH1, TMH7-9, and TMH11 from the
DPA-bound EmbB protomer and the TMH10, TMH13, and
TMH14 from the other protomer. DPA is in pink. (B) The
complete DPA in the groove, with surrounding TMHs from both
protomers. Cryo-EM map is shown in colored mesh. (C) The
DPA-bound cavity viewed just above the membrane surface is
bordered by PL2 which contains the catalytically relevant D
(285)D(286)X motif, PL5 which is organized as two short α-
helices (α5 and α6), and the mixed α/β subdomain of PDC. DPA
is shown in pink. (D) Zoom-in view of the catalytic cavity,
showing side-chains of residues interacting with the DPA head-
group and a putative metal ion. Interactions are indicated by
dashed lines. (E) The hydrophobic decaprenyl tail of DPA in the
groove of the dimer interface, making several hydrophobic
interactions, and a C-H···π-interaction with F670 from the empty
protomer. (F) DPA binding cavity viewed from the periplasm.
EmbB protomers from the “resting” state (purple) and “donor-
bound” active state (blue) are superimposed. The dotted line
from Q502 to G521 indicates a disordered loop in the “resting”
state, which is stabilized in the active state through interactions
with DPA. See also Figs. S1G, S5 and S8.
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formation of the new glycosidic bond at the anomeric carbon
(Lairson et al., 2008). Emb proteins are believed to be
inverting enzymes based on the fact that nearly all of the
arabinose residues in the DPA-involved extension of AG are
in an α-configuration (Jankute et al., 2015) (except for the
non-reducing end of AG catalyzed by AftB (Seidel et al.,
2007)), while DPA is in a β-configuration (Lee et al., 1995).
For a conventional inverting glycosyltransferase reaction,
upon both substrates (the donor and acceptor) reaching the
catalytic site, a key catalytic step relies on an active site side-
chain, which serves as a base catalyst that deprotonates the
nucleophile of the acceptor, enabling the following nucle-
ophilic attack at the anomeric carbon (Breton et al., 2012). In
our structure, the arabinose moiety of DPA is positioned
between two acidic residues D285 and E313 in the catalytic
pocket (Fig. 3D). D285 belongs to the highly conserved DDx
GT-C motif and is the predicted catalytically essential resi-
due (Berg et al., 2005). Mutation of this residue in EmbB in
this study and the equivalent residue D279 in EmbC as
previously reported (Berg et al., 2005) led to a complete loss
of activity (Fig. S5B). In EmbB, D285 locates at the junction
of two cavities, one of which harbors the arabinose moiety
and phosphate group of DPA, and the other, opposite to the
DPA cavity, provides polar access to the dimer interface
above the membrane boundary (Figs. 5A, 5B, and 5D).
Altogether, this suggests that D285 is likely the key active
site residue involved in catalysis. In our structure, DPA aligns
its C5 atom close to D285, whereas the C1 atom is
approximately 8 Å from the side-chain of D285. It is specu-
lated that a further conformational change is required, pos-
sibly upon acceptor binding, allowing the DPA to move
deeper into the cavity and reorient its C1 atom for α(1→3)
glycosidic bond formation. This shift could involve a reposi-
tioning of the phosphate group much deeper into the DPA
cavity and closer to D285.
EmbB catalyzes the penultimate step of AG synthesis.
We have previously reported that EmbB functions in a
coordinating way with EmbA (Zhang et al., 2020), never-
theless, our cell-free assay has confirmed that purified EmbB
alone is functional using NV6 as acceptor. Thus, it can be
inferred that EmbB may play dual roles in cells, by either
forming a homodimer or a heterodimer with EmbA,
depending on the physiological concentration of these pro-
teins. Therefore, the native acceptor of EmbB could be a
relatively mature arabinan chain before the terminal 3-arm
branch of the characteristic hexa-arabinan motif (Fig. 1A).
The possible acceptor entry pathway could be deduced
based on the location of the identified donor binding cavity
and the putative active site. This polar pathway as men-
tioned above is a tryptophan-rich region that we refer to as
the “W-pathway” (Fig. 5A). This W-pathway is formed by a
series of tryptophan residues W308, W504, W505, W972,
and W1012. The first three tryptophan residues, located on
the DDX-motif-containing PL2 and conformational change
modulator PL5, extend to the arabinose moiety of DPA, while
the latter two tryptophan residues are located on the mixed
α/β fold subdomain of PDC. The role of W972 was previously
reported to be critical in terms of both of the binding affinity
with acceptor and the enzymatic activity in EmbC (W985 in
EmbC corresponds to W972 in EmbB) (Alderwick et al.,
2011). These tryptophan residues are only partially con-
served amongst EmbA, EmbB, and EmbC. The differences
might reflect the fact that Emb proteins are different enzymes
with different substrate specificities. Furthermore, previous
studies have attributed the C-terminal domain of the Emb
proteins to a critical role in acceptor substrate recognition
and arabinan chain extension (Shi et al., 2006; Alderwick
et al., 2011). Consistent with this, in the active state struc-
ture, several regions of the PDC are missing in the DPA
unbound EmbB protomer (Figs. 5D and S3E). The flexibility
of these missing regions could be the result of the absence
of the acceptor when the EmbB2-AcpM2 complex is acti-
vated by the donor. Consequently, this region in PDc may
outline a fairly broad and open pathway leading straight into
AcpM
AcpM
S41
D61
D53
EmbB
CL1
R249
R545
R253
PDN PDC
Membrane
Periplasm
Cytoplasm
α3
α2
Figure 4. EmbB-AcpM interaction and implications of by-product recycling. Interface of EmbB-AcpM interaction, AcpM has a
four-helix topology. Three pairs of residues participate in the EmbB-AcpM interaction, side-chains are shown as sticks.
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the W-pathway headed by W504 which locates in the dimer
interface (Fig. 5D), thus indicating a macroscopic acceptor
entry pathway.
Proposed catalytic cycle for the arabinosyltransferase
complex
In this study, we have determined the structures of a sub-
strate unbound EmbB2-AcpM2 complex in a presumed
resting state and a donor DPA-bound pre-catalytic
conformation which we define as the “active” state. The two
structures of EmbB2-AcpM2 suggest that the binding of
substrates is a sequentially coupled process with substantial
conformational changes upon the binding of the two
substrates.
We hypothesize that DPA binding activates the EmbB
dimer by triggering conformational changes. Once the
EmbB2-AcpM2 complex is activated, the glycosyltransferase
reaction can occur in the following defined steps (Fig. 6).
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DPADPA
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2 1
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Figure 5. Active site and possible acceptor pathway. (A) DPA bound cavity viewed from PDC. An open path (W-pathway) between
W1012 and W505 connecting to the DPA arabinose moiety at the dimer interface is indicated by the dashed curves. Surrounding
side-chains interacting with DPA are shown as stick models. (B) Orthogonal view of (A) with the W-pathway to the DPA arabinose
moiety is indicated by a dashed circle. (C) Orthogonal and zoom-in view of (B). (D) Flexibility of PLs in the empty protomer suggests
an extending of the presumed acceptor approaching pathway in panel (A) which is indicated by W504 at the entrance. See also
Fig. S3E.
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A-I. The acceptor is recognized and threaded by PDC and
enters the active site through the W-pathway, forming an
enzyme-donor-acceptor ternary complex (A-II) ready for the
reaction. The DPA bound EmbB2-AcpM2 structure in this
study represents an intermediate state before C1 of DPA
reaches the optimal position for catalysis. Hence, to form the
ternary complex a series of precisely arranged conforma-
tional changes are required to allow both substrates to be
oriented optimally.
A-II. Based on the catalytically essential role of D285 and
canonical mechanism of an inverting glycosyltransferase
(Qasba et al., 2005; Lairson et al., 2008), the following is
rationally proposed: D285 deprotonates the hydroxyl group
on the C3 carbon of the acceptor and activates this hydroxyl
group for a nucleophilic attack on the C1 carbon of DPA. A
new glycosidic bond is formed (A-III) allowing the newly
formed arabinan product and DP (the leaving group) to
release from the active site.
DPA
Acceptor
Product
R
A-I
Resting state
A-II
A-III
A-IV
Enzyme-Donor-Acceptor 
ternary complex 
Enzyme-Donor 
complex 
Enzyme-Product-By product 
ternary complex 
DPA
DP
R
es
tin
g
Activation
Reaction
Figure 6. A proposed catalytic cycle for the arabinosyltransferase complex EmbB2-AcpM2. The components of the complex
are colored as in Fig. 1B. The arabinofuranosyl motif of the donor (tetraarabinan) and product (pentaarabinan) are depicted as a chain
of cyan pentagons (the arabinose moiety transferred from DPA is in red). Donor (DPA) and by-product (DP) molecules shown as
spheres in their different locations are colored as Fig. 4A and 4B. The bold arrow lines in grey, red and blue indicate the resting state,
activation and processing states during turn-over. Dashed arrow lines indicate a possible recycle mechanism of DP through a
switching of DP-carrying AcpM and a hollow one. Different states in the active phase are labeled as A-I, A-II, A-III, A-IV.
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A-III. Overall, functional studies confirm that EmbB cat-
alyzes arabinose chain α(1→3) branching with the subse-
quent product utilized by AftB for the terminal β(1→2) linkage
at the non-reducing end of AG. Therefore, it is plausible that
product release (A-IV) could be coupled instantaneously with
a new round of DPA binding (A-I).
Structural mapping of ethambutol resistance
associated mutations and its potential binding site
In this study, we have shown that anti-TB drug ethambutol
inhibits the α(1→3) arabinosyltransferase activity of purified
EmbB protein. This agrees with the fact that branching of the
terminal hexaarabinan motif in AG can be inhibited by
ethambutol (Lee et al., 2005). Numerous mutations in embB
are causally associated with resistance to ethambutol, but
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Figure 7. Mapping of ethambutol-resistant mutation sites. (A) Log-Scaled histogram of the occurrence of the top 30 frequent
ethambutol-resistant mutations in EmbB in 61 studies collected from the drug-resistance database, MycoResistance, and their
positions on the DPA-bound EmbB structure, most notably around DPA binding cavity. Mutations with more than 20 occurrences are
colored in yellow, and those with more than 1,000 occurrences are in red. (B) MST assays for the binding of ethambutol to wild-type
EmbB treated with 2× MIC of BTZ-043 or inhibitor-free during culture and ethambutol resistant mutation hotspot M292L represented
by red sphere in (A). Error bars represent mean ± SEM based on three independent measurements. Binding curves and KD values
are also shown. See also Figs. S7 and S8.
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their effects on EmbB structure and function remain unclear.
The three-dimensional structure of EmbB provides an
unprecedented opportunity to understand the role that the
embB mutations play in the development of ethambutol
resistance in M. tuberculosis. We selected the top 30 most
frequent ethambutol-resistant mutations of EmbB in 1,814
strains from 61 studies in a manually collated drug-resis-
tance database MycoResistance (Dai et al., 2019) (Figs. 7A
and S8). Upon mapping these onto the DPA-bound EmbB
structure, we find that most of the mutations concentrate in a
radial region centered on the DPA-bound pocket (Fig. 7A).
M306 (equivalent to Msm M292) in Mtb EmbB which is the
most common clinical mutation associated with ethambutol
resistance (Ramaswamy et al., 2000; Lee et al., 2005; Safi
et al., 2008) is, as expected, also the most predominant
(1243/2353) in our analysis (Fig. 7A). Clinical isolate muta-
tions include M306L, M306V, M306I and M306T substitu-
tions in Mtb (Lee et al., 2002; Sun et al., 2018). In Msm,
M292T mutation results in a 60-fold increase in MIC (Lety
et al., 1997). In our cell-free enzymatic activity assay, mutein
M292L demonstrates clear resistance to ethambutol
(Fig. S5A). Meanwhile, the binding affinity of ethambutol to
this mutein also significantly decreases (Fig. 7B).
The recently reported structure of the ethambutol bound
EmbA-EmbB complex enables us to analyze the structural
features of the potential drug binding pockets of EmbB2 in
this study. When superimposing the EmbB protomer from the
EmbB2 in its resting state onto the EmbB subunit of
ethambutol-bound EmbA-EmbB complex (Zhang et al.,
2020), residues including the catalytic site D285 on EmbB2
were obsereved in the similar position (Figure S7A). Thus it
is possible the ethambutol inhibition mode on EmbB2 similar
to that on EmbA-EmbB complex by inhibiting substrate
binding. Notable shifting (2.9∼4.0 A°) were observed on
E313 on PL2 and H580 on PL6 (Figure S7A), likely due to
ethambutol binding. The binding affinity of EmbB with
ethambutol is greatly enhanced (KD = 1.58 μmol/L) (Fig. 7B)
when a DPA synthesis inhibitor, BTZ043 (Makarov et al.,
2009), was added during cell culture to obtain overex-
pressed EmbB protein in a relatively low-abundance DPA
environment, which could support this speculation. The
competitive inhibition hypothesis of ethambutol is also in
agreement with a previous DPA recognition study which
demonstrated a rapid accumulation of DPA in ethambutol
treated Msm cells(Wolucka et al., 1994).
These analyses will facilitate further experimental studies
aimed at understanding how mutations in EmbB and other
Emb proteins lead to ethambutol resistance. To be noted, not
all ethambutol-resistant strains have embB mutations (Al-
caide et al., 1997), suggesting that further studies on other
resistance associated proteins or pathways are necessary to
complete a comprehensive understanding of the mecha-
nisms of ethambutol resistance.
CONCLUSIONS
In this study, cryo-EM single-particle analysis revealed con-
formational heterogeneity in arabinosyltransferase complex
EmbB2-AcpM2 which we ascribe to evidence for a “resting”
and “donor-bound active” state. An acceptor recognition and
entry pathway is proposed. We have also characterized
EmbB as an α(1→3) arabinosyltransferase and confirmed it
is a target of ethambutol. Thus, our work not only unravels
the molecular mechanisms involved in substrate recognition
for this arabinosyltransferase but also provides a much-an-
ticipated foundation for developing improved anti-TB drugs
such as inert DPA analogues.
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